In a stark turnabout from last year, Forest Laboratories and cantankerous investor Carl Icahn are making nice ahead of the company's annual shareholder meeting.
Mumbai-based Elder Pharmaceuticals may be the next company to get snatched up by a Western drugmaker looking to expand into India. Elder, currently struggling amid competition and rising debts, is on the sales block, or so the rumors go.
Elan has ditched a complaint against Royalty Pharma in a U.S. District Court, having filed the lawsuit against Royalty for lacking disclosures in its takeover bid last week. Ireland-based Elan is claiming a victory because it dropped the lawsuit after Royalty responded with additional disclosures in its latest and increased bid to acquire Elan.
It's all about choices. It is a week before shareholders will decide whether to let run with the current management or cash in on the sure deal offered by Royalty Pharma, but Elan Pharmaceutical investors have a handful of choices to sort through before they vote.
AstraZeneca's first-quarter earnings report was a stark indication of why its new CEO Pascal Soriot is scrambling to buy some new drugs the company can lean on.
Despite the growth potential in Galenika's home country of Serbia, Valeant was the only suitor so far willing to enter a market rife with corruption. Now, it has backed out of its offer to buy the ailing state-run drugmaker amid agitation in Belgrade over privatization.
As PRA mulls an IPO, three private equity heavyweights are reportedly looking to bid on the CRO, and current owner Genstar Capital could well be pushing talk of going public just to tick up the asking price.
The Pearl Therapeutics buyout gives AstraZeneca's late-stage development director Briggs Morrison a Phase III respiratory therapy just days after the pharma giant was forced to throw in the towel on the rheumatoid arthritis drug fostamatinib.
ICU Medical's bid to sell itself kicks into its next round this week, with the California device maker expected to seek second-round bids. As Reuters reports, a few interested parties have already emerged, including larger rival CareFusion, Hospira and at least one private equity firm.
Elan and Royalty Pharma have been in a rapid back and forth of one-upmanship to win the hearts and votes of Elan shareholders. But the latest offer from Royalty may turn the the tide.